.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Randomized evidence and international treatment recommendations continue to support methotrexate as a foundational conventional synthetic DMARD for many patients with newly diagnosed rheumatoid arthritis. Early treatment improves the likelihood of achieving low disease activity or remission and reduces the risk of progressive joint damage. For general physicians, the practical issue is not simply choosing methotrexate but implementing it safely: baseline blood counts, liver function, renal function, hepatitis screening where appropriate, folic-acid supplementation, pregnancy considerations and regular laboratory monitoring are all important. Treatment response should be assessed at defined intervals, and therapy escalated when the patient is not moving toward the target. Rheumatoid arthritis care also requires management of cardiovascular risk, vaccination and bone health. The modern treat-to-target model therefore turns methotrexate initiation into the first step of an adaptive pathway rather than a final decision. Prompt specialist referral is warranted when diagnosis is uncertain, extra-articular disease is present or disease activity remains high despite initial treatment.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Randomized evidence and international treatment recommendations continue to support methotrexate as a foundational conventional synthetic DMARD for many patients with newly diagnosed rheumatoid arthritis. Early treatment improves the likelihood of achieving low disease activity or remission and reduces the risk of progressive joint damage. For general physicians, the practical issue is not simply choosing methotrexate but implementing it safely: baseline blood counts, liver function, renal function, hepatitis screening where appropriate, folic-acid supplementation, pregnancy considerations and regular laboratory monitoring are all important. Treatment response should be assessed at defined intervals, and therapy escalated when the patient is not moving toward the target. Rheumatoid arthritis care also requires management of cardiovascular risk, vaccination and bone health. The modern treat-to-target model therefore turns methotrexate initiation into the first step of an adaptive pathway rather than a final decision. Prompt specialist referral is warranted when diagnosis is uncertain, extra-articular disease is present or disease activity remains high despite initial treatment.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
